134 related articles for article (PubMed ID: 32641325)
1. Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients.
Roman E; Cardoen B; Decloedt J; Roodhooft F
BMJ Open; 2020 Jul; 10(7):e035389. PubMed ID: 32641325
[TBL] [Abstract][Full Text] [Related]
2. A time-driven activity-based costing approach for identifying variability in costs of childbirth between and within types of delivery.
Dubron K; Verschaeve M; Roodhooft F
BMC Pregnancy Childbirth; 2021 Oct; 21(1):705. PubMed ID: 34670514
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
4. Direct medical costs of breast cancer in Jordan: cost drivers and predictors.
Mousa R; Hammad E; Melhem J; Al-Jaghbir M
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):647-654. PubMed ID: 33353434
[No Abstract] [Full Text] [Related]
5. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.
Elidrissi Errahhali M; Elidrissi Errahhali M; Ouarzane M; El Harroudi T; Afqir S; Bellaoui M
BMC Womens Health; 2017 Jan; 17(1):3. PubMed ID: 28068979
[TBL] [Abstract][Full Text] [Related]
6. Metastatic breast cancer: we do need primary cost data.
Bonastre J; Jan P; Barthe Y; Koscielny S
Breast; 2012 Jun; 21(3):384-8. PubMed ID: 22520336
[TBL] [Abstract][Full Text] [Related]
7. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
9. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
Van Vlaenderen I; Canon JL; Cocquyt V; Jerusalem G; Machiels JP; Neven P; Nechelput M; Delabaye I; Gyldmark M; Annemans L
Acta Clin Belg; 2009; 64(2):100-12. PubMed ID: 19432022
[TBL] [Abstract][Full Text] [Related]
11. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
13. Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing.
Wilkinson AN; Seely JM; Rushton M; Williams P; Cordeiro E; Allard-Coutu A; Look Hong NJ; Moideen N; Robinson J; Renaud J; Mainprize JG; Yaffe MJ
Curr Oncol; 2023 Aug; 30(9):7860-7873. PubMed ID: 37754486
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
15. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Hooiveld MJ; Neven P; Raaijmakers JA; Schellens JH
Eur J Cancer Care (Engl); 2015 May; 24(3):340-54. PubMed ID: 25413216
[TBL] [Abstract][Full Text] [Related]
16. [Breast Cancer: Value-Based Healthcare, Costs and Financing].
Harfouche A; Silva S; Faria J; Araújo R; Gouveia A; Lacerda M; D'Orey L
Acta Med Port; 2017 Nov; 30(11):762-768. PubMed ID: 29279067
[TBL] [Abstract][Full Text] [Related]
17. [Cost of breast cancer treatment by clinical stage in the Basque Country, Spain].
Arrospide A; Soto-Gordoa M; Acaiturri T; López-Vivanco G; Abecia LC; Mar J
Rev Esp Salud Publica; 2015; 89(1):93-7. PubMed ID: 25946589
[TBL] [Abstract][Full Text] [Related]
18. Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs.
Han K; Yap ML; Yong JH; Mittmann N; Hoch JS; Fyles AW; Warde P; Gutierrez E; Lymberiou T; Foxcroft S; Liu FF
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):587-93. PubMed ID: 27139262
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
20. The costs of breast cancer prior to and following diagnosis.
Broekx S; Den Hond E; Torfs R; Remacle A; Mertens R; D'Hooghe T; Neven P; Christiaens MR; Simoens S
Eur J Health Econ; 2011 Aug; 12(4):311-7. PubMed ID: 20306109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
